AU2159895A - Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains - Google Patents

Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains

Info

Publication number
AU2159895A
AU2159895A AU21598/95A AU2159895A AU2159895A AU 2159895 A AU2159895 A AU 2159895A AU 21598/95 A AU21598/95 A AU 21598/95A AU 2159895 A AU2159895 A AU 2159895A AU 2159895 A AU2159895 A AU 2159895A
Authority
AU
Australia
Prior art keywords
domains
materials
methods
molecular interactions
identifying inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU21598/95A
Inventor
Martyn C Botfield
Joan S Brugge
Richard J Rickles
Mark J Zoller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Pharmaceuticals Inc
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Publication of AU2159895A publication Critical patent/AU2159895A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C07K2319/715—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16 containing a domain for ligand dependent transcriptional activation, e.g. containing a steroid receptor domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/72—Fusion polypeptide containing domain for protein-protein interaction containing SH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
AU21598/95A 1994-03-11 1995-03-13 Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains Abandoned AU2159895A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20983594A 1994-03-11 1994-03-11
US209835 1994-03-11
US36983295A 1995-01-06 1995-01-06
US369832 1995-01-06
PCT/US1995/003208 WO1995024419A1 (en) 1994-03-11 1995-03-13 Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains

Publications (1)

Publication Number Publication Date
AU2159895A true AU2159895A (en) 1995-09-25

Family

ID=26904553

Family Applications (1)

Application Number Title Priority Date Filing Date
AU21598/95A Abandoned AU2159895A (en) 1994-03-11 1995-03-13 Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains

Country Status (3)

Country Link
EP (1) EP0750630A4 (en)
AU (1) AU2159895A (en)
WO (1) WO1995024419A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184205B1 (en) * 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
ATE322684T1 (en) * 1994-07-22 2006-04-15 Univ North Carolina SRC SH3 BINDING PEPTIDES AND METHOD FOR ISOLATION AND USE THEREOF
US6303574B1 (en) 1994-07-22 2001-10-16 The University Of North Carolina At Chapel Hill Scr SH3 binding peptides and methods of isolating and using same
US5888763A (en) * 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
US6309820B1 (en) 1995-04-07 2001-10-30 University Of North Carolina At Chapel Hill Polypeptides having a functional domain of interest and methods of identifying and using same
WO1996031625A1 (en) 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
GB2311067B (en) * 1996-01-08 2000-03-29 Yamanouchi U K Ltd Proline rich peptides derived from the rasgap-associated protein P62
US6303319B1 (en) * 1996-02-23 2001-10-16 Ariad Pharmaceuticals, Inc. Cell based assay for identifying sh2-domain-specific signal transducer antagonist
US7279548B2 (en) 1996-04-03 2007-10-09 Cytogen Corporation Identification and isolation of novel polypeptides having WW domains and methods of using same
JP2000508923A (en) * 1996-04-26 2000-07-18 マサチューセッツ・インスティテュート・オブ・テクノロジー 3-Hybrid screening assay
US6723694B1 (en) * 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
EP1077997A2 (en) * 1998-05-21 2001-02-28 THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING (McGILL UNIVERSITY) Inhibition of the binding of protein tyrosine phosphatase pest to domains of signalling proteins
AU4761100A (en) 1999-05-26 2000-12-18 Kalle Saksela Methods and materials for generating sh3 domains with tailored binding properties
US20020002239A1 (en) * 1999-12-29 2002-01-03 Tanaka Richard D. Binding of polyamides to proteins having SH3 or WW domains
EP1432729B1 (en) * 2001-07-02 2008-11-12 Merrion Research III Limited Peyers's patch and/or m-cell targeting ligands
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
AU2003258022A1 (en) 2002-08-02 2004-02-23 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
WO2004039318A2 (en) 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
US7129214B2 (en) 2002-12-10 2006-10-31 Oscient Pharmaceuticals Corporation Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
ES2354881T3 (en) * 2003-06-20 2011-03-18 Mayo Foundation For Medical Education And Research ISOFORMS OF CEREBRAL NATURAL PEPTIDE.
BRPI0716416A2 (en) 2006-08-08 2016-10-11 Mayo Foundation substantially pure polypeptide between 37 and 47 amino acid in length, isolated nucleic acid, vector: host cell and pharmaceutical composition
WO2009026622A1 (en) * 2007-08-24 2009-03-05 Mylexa Pty Limited Modulators of hypersensitivity reactions
WO2009036448A2 (en) 2007-09-15 2009-03-19 Mayo Foundation For Medical Education And Research Natriuretic peptide receptor-c agonists
US8088890B2 (en) * 2008-09-26 2012-01-03 Fibrex Medical Research & Development Gmbh Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
JP2014525439A (en) 2011-08-30 2014-09-29 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Natriuretic polypeptide
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
EP2752196A1 (en) * 2013-01-03 2014-07-09 Université Bordeaux Segalen Selective nox-1 inhibitor peptides and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
CA2054602C (en) * 1991-10-31 2003-04-22 Anthony Pawson Method for assaying for a substance that affects an sh2-phosphorylated ligand regulatory system

Also Published As

Publication number Publication date
WO1995024419A1 (en) 1995-09-14
EP0750630A1 (en) 1997-01-02
EP0750630A4 (en) 1998-01-07

Similar Documents

Publication Publication Date Title
AU2159895A (en) Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains
HUP9700602A3 (en) New inhibitors of bone-resorption and vitronectine-receptor-antagonists
AU3395597A (en) Identification and comparison of protein-protein interactions and inhibitors thereof
AU2819397A (en) Inhibitors of glycogen synthase kinase-3 and methods for identifying and using the same
AU6977998A (en) Method and apparatus for ionized sputtering of materials
IL122186A (en) Heterocycles as inhibitors of leucotype adhesion and as vla-4-antagonists
AU2996897A (en) Inhibitors of microsomal triglyceride transfer protein and method
AU4231197A (en) Hppd gene and inhibitors
HUP9901321A3 (en) Methods and compositions for determining the sequence of nucleic acid molecules
AU3793697A (en) Apparatus and methods for the disinfection of fluids
AU6136094A (en) Apolipoprotein b mrna editing protein compositions and methods
AUPN992596A0 (en) Magnetic detection of discontinuities in magnetic materials
AU6659698A (en) Compositions, methods, kits and apparatus for determining the presence or absence of target molecules
AU3294897A (en) Method and apparatus for sensing the presence of microbes
AU2967692A (en) Improved composition and device for urinary protein assay and method of using the same
AU6485996A (en) Methods and compositions for modulation and inhibition of teomerase
AU5599598A (en) Inhibitors of glycosyltransferases
AU4634896A (en) Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods
AU9589798A (en) Composition and method for inhibiting polymerization during the anaerobic production of styrene
AU5654696A (en) Inhibitors of fibrin cross-linking and/or transglutaminases
DE69525146D1 (en) Audio processing unit for mixing the L channel and R channel of a CD / CD-I audio signal
AU4064897A (en) Mammalian ribonuclease inhibitors and use thereof
AU7395194A (en) Neomorphic ibuprofen and methods of using same
AU2479495A (en) Materials and methods for the detection of mycobacteria
AU8010698A (en) Method and device for enabling non-destructive determination of the elasticity of materials